SYK - Stryker Corporation
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
What happened Stryker (NYSE: SYK) said Kevin Lobo will become Executive Chair and Spencer Stiles will become CEO on January 1, 2027. The company said the move follows a planned succession process. Stiles, now President and COO, will also join Stryker's Board at that time. Lobo joined Stryker in 2011 as Group President, became CEO
Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, today announced that as part of a planned succession process, Kevin Lobo will transition to the role of Executive Chair of the Board of Directors, effective January 1, 2027. Spencer Stiles, currently President and Chief Operating Officer of Stryker, will succeed Lobo as Chief Executive Officer and will also be appointed as a member of the company's Board at that time.
Stryker is upgraded to 'Strong Buy' after a significant price pullback to $275, offering compelling value relative to historical valuation. SYK demonstrates robust organic sales growth, balanced across geographies and segments, with strong demand and elevated equipment backlogs. Key growth drivers include Mako robotic-assisted procedures, ASC expansion, and Smart Care platform integration, supporting double-digit EPS growth expectations.
Boston, Massachusetts--(Newsfile Corp. - October 2, 2026) - Block & Leviton is investigating Stryker Corporation (NYSE: SYK) for potential securities law violations. Investors who have lost money in their Stryker investment should contact the firm to learn more about how they might recover those losses.
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
SAN FRANCISCO, Oct. 1, 2026 /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists. The move lower wiped out over $10 billion of Stryker's market capitalization.
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Portage, Michigan, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, October 29, 2026, to discuss its third quarter 2026 financial results.
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Engineers Gate Manager LP decreased its stake in Stryker Corporation (NYSE: SYK) by 96.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,117 shares of the medical technology company's stock after selling 27,714 shares during the quarter.
Envestnet Asset Management Inc. lifted its position in shares of Stryker Corporation (NYSE: SYK) by 12.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 650,461 shares of the medical technology company's stock after buying an additional 70,634
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK).
ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.
GD's Stryker contract modification lifts cumulative value to $278.9M, supporting Land Systems demand through December 2028.
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists.
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Boston, Massachusetts--(Newsfile Corp. - September 18, 2026) - Block & Leviton is investigating Stryker (NYSE: SYK) for potential securities law violations. Investors who have lost money in their Stryker investment should contact the firm to learn more about how they might recover those losses.